Skip to Main Content

A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors


Phase I

Phase I

What is the purpose of this trial?

The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with BAY1895344 in combination with pembrolizumab. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with pembrolizumab, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication, BAY1895344, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor.

  • Trial with
    Bayer Healthcare Pharmaceuticals, Inc.
  • Start Date
  • End Date

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 877.978.8343

  • Last Updated
  • Study HIC